BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2023 Earnings Conference Call May 3, 2023 8:30 AM ET

Company Participants

John Bluth - Investor Relations

Jon Stonehouse - Chief Executive Officer

Anthony Doyle - Chief Financial Officer

Charlie Gayer - Chief Commercial Officer

Helen Thackray - Chief R&D Officer

Conference Call Participants

Allison Bratzel - Piper Sandler

Jon Wolleben - JMP Securities

Tazeen Ahmad - Bank of America

Stacy Ku - Cowen & Co.

Justin Kim - Oppenheimer & Co. Inc.

Serge Belanger - Needham & Company

Liisa Bayko - Evercore ISI

Brian Abrahams - RBC Capital Markets

Gena Wang - Barclays

Maury Raycroft - Jefferies, LLC

Operator

Good morning and welcome to the BioCryst Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference to John Bluth at BioCryst. Please go ahead.

John Bluth

Thank you very much. Good morning and welcome to BioCryst's first quarter 2023 corporate update and financial results conference call. Today’s press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we will answer your questions.

Before we begin, please note that today’s conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company’s future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company’s documents filed with the Securities and Exchange Commission, which can be accessed on our website.

I’d now like to turn the call over to Jon Stonehouse.

Jon Stonehouse

Thanks, John. The launch of ORLADEYO remains very strong now entering the third year. Charlie will share the details and when you hear the total number of patients on therapy and the growth rates of adding new patients both year-over-year and quarter-over-quarter, you should understand why we remain very confident in our guidance of no less than $320 million this year and $1 billion at peak.

The large base of patients on therapy and the consistent number of new patient starts each quarter reflect a steady upward trajectory. And this is just the beginning as there is so many more patients yet to try ORLADEYO. We have a once a day therapy in an injectable marketplace.